Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01910389 · ClinicalTrials.gov registry record · Phase 3
Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure
A Phase 3 study, sponsored by Carelon Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT01910389 is a Phase 3 study that was terminated before completion, run by Carelon Research. The registered enrollment target is 23 participants.
The verdict
NCT01910389, a Phase 3 study, was terminated before completion, sponsored by Carelon Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is a multi-center, prospective, randomized, double blind, placebo-controlled clinical trial. Subjects in the study will be adults with New York Heart Association (NYHA) Class II-IV heart failure (HF) due to left ventricular systolic dysfunction (LVSD), left ventricular ejection fraction (LVEF) \<0.40, and secondary pulmonary hypertension (PH). The purpose of the study is to evaluate the safety, effectiveness, and effects of tadalafil compared to placebo on the subjects' functional capacity / quality of life.
Interventions
- DRUG Tadalafil
- DRUG Placebo for tadalafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01910389
The ClinicalTrials.gov registry entry for NCT01910389 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tadalafil is the first listed.
NCT01910389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01910389 about?
NCT01910389 is a clinical study titled "Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure". This study is a multi-center, prospective, randomized, double blind, placebo-controlled clinical trial. Subjects in the study will be adults with New York Heart Association (NYHA) Class II-IV heart failure (HF) due to left ventricular systolic dysfunction (LVSD), left ventricular ejection fraction (...
What is the current status of trial NCT01910389?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2013-11. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01910389?
The interventions under investigation include: Tadalafil (DRUG), Placebo for tadalafil (DRUG).
Who is sponsoring clinical trial NCT01910389?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.